

Discovery and Pharmacological Characterization of Novel Quinazoline-based PI3K delta-selective Inhibitors

Klemens Hoegenauer, Nicolas Soldermann, Frederic Stauffer, Pascal Furet, Nadege Graveleau, Alexander B. Smith, Christina Hebach, Gregory J. Hollingworth, Ian Lewis, Sascha Gutmann, Gabriele Rummel, Mark Knapp, Romain M Wolf, Joachim Blanz, Roland Feifel, Christoph Burkhart, and Frederic Zecri

ACS Med. Chem. Lett., **Just Accepted Manuscript** • DOI: 10.1021/acsmedchemlett.6b00119 • Publication Date (Web): 02 Jun 2016

Downloaded from <http://pubs.acs.org> on June 3, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Discovery and Pharmacological Characterization of Novel Quinazoline-based PI3K delta-selective Inhibitors

Klemens Hoegenauer^{*a}, Nicolas Soldermann^{*a}, Frédéric Stauffer^a, Pascal Furet^a, Nadege Graveleau^a, Alexander B. Smith^a, Christina Hebach^a, Gregory J. Hollingworth^a, Ian Lewis^a, Sascha Gutmann^b, Gabriele Rummel^b, Mark Knapp^c, Romain M. Wolf^a, Joachim Blanz^c, Roland Feifel^c, Christoph Burkhardt^d and Frédéric Zécri^a

^aGlobal Discovery Chemistry, ^bCenter for Proteomic Chemistry, ^cMetabolism and Pharmacokinetics, ^dAutoimmunity, Transplantation and Inflammation, Novartis Institutes for BioMedical Research, Novartis Campus, CH-4002 Basel, Switzerland; ^eGlobal Discovery Chemistry, 5300 Chiron Way, Emeryville, California 94608, USA.

ABSTRACT: Inhibition of the lipid kinase PI3K δ is a promising principle to treat B- and T-cell driven inflammatory diseases. Using a scaffold deconstruction–reconstruction strategy, we identified 4-aryl quinazolines that were optimized into potent PI3K δ isoform selective analogues with good pharmacokinetic properties. With compound **11**, we illustrate that biochemical PI3K δ inhibition translates into modulation of isoform dependent immune cell function (human, rat and mouse). After oral administration of compound **11** to rats, proximal PD markers are inhibited, and dose-dependent efficacy in a mechanistic plaque forming cell assay could be demonstrated.

KEYWORDS *Phosphoinositide-3-kinase delta inhibitor, PI3K δ inhibitor, lead optimization, structure-activity relationship, PK/PD studies, B cell inhibition*

Phosphoinositide-3-kinases (PI3K) are lipid kinases responsible for the generation of the second messenger phosphatidylinositol (3,4,5) triphosphate (PIP3) from the substrate phosphatidylinositol (4,5) biphosphate (PIP2) leading to phosphorylation of Akt and subsequent progression of cell differentiation, proliferation, motility and survival.^{1,2} PI3K have been classified according to their structural and functional properties. The class I enzymes can be divided into IA and IB PI3K. In mammals, class IA PI3K includes three different isoforms: PI3K α , PI3K β , and PI3K δ while class IB includes PI3K γ . These enzymes are heterodimers consisting of the p110 catalytic subunits (p110 α , p110 β , p110 γ , and p110 δ) and a regulatory subunit (most commonly p85 α).³

During the past decade there has been a great deal of interest in the development of inhibitors of the class I PI3K family. Initially, broad-spectrum inhibitors of the α , β , γ and δ isoforms were targeted as potential oncology therapeutics.^{4–6} However, the recognition that the γ and δ isoforms are predominantly expressed in leukocytes and play a critical role in T and B cell function⁷ led to speculation that selective inhibitors of these isoforms could offer potential as therapeutics for the treatment of allergic and inflammatory diseases.⁸ Moreover, specifically targeting PI3K δ should avoid potential side effects associated with the ubiquitously expressed PI3K α and β isoforms.^{9–11} PI3K δ is expressed primarily in hematopoietic cells and its functional relevance in the activation of leukocytes of the adaptive as well as the innate immune

system has been demonstrated in genetically modified mice (PI3K $\delta^{\text{D910A/D910A}}$ knock-in and PI3K $\delta^{-/-}$)^{12–14} and through the use of specific tool compounds in in vitro and in vivo preclinical models.^{15–17} The strong biological rationale led us and others^{18–21} to initiate a medicinal chemistry program aimed at the discovery of PI3K δ -selective inhibitors with suitable properties and efficacy to allow for development as an anti-inflammatory therapeutic.

Our efforts towards the identification of PI3K inhibitors which are selective for the delta isoform started with imidazoquinoline **1** (BEZ235, Table 1), a pan-PI3K/mTOR inhibitor with potent anti-tumor activity.²² We had a good understanding of the binding mode of imidazoquinoline **1** based on docking studies of numerous compounds of this scaffold into a homology model of PI3K α which was built based on the reported x-ray structure of PI3K γ kinase domain.²³ Using a similar homology model for PI3K δ , we hypothesized that we would gain selectivity by reaching out to the non-conserved amino acid residues that line the entrance of the ATP binding site (see Supplementary Figure 3). To this end, we first deconstructed the imidazoquinoline to the quinazoline fragment **2a** (Table 1) to remove the structural elements which interact in the selectivity pocket and contribute significantly to the strong affinity for mTOR. Quinazoline **2a** contains some crucial core elements for PI3K binding affinity, namely the position-1 nitrogen acting as a hinge binder and the quinoline which fills the affinity-pocket (conserved over all PI3K isoforms). We detected submicromolar activity for PI3K α , only, making this compound a very ligand efficient PI3K α inhibitor. Some marginal activity on PI3K δ was retained whilst the affinity towards all other PI3K isoforms as well as mTOR was above the highest test concentration. Introduction of a 4-phenyl substituent (**2b**) increased the activity for PI3K α and δ considerably with some emerging selectivity over the β and γ isoforms. Modification of the substitution pattern of the phenyl group led to some additional favorable modulation of the PI3K δ (higher) and mTOR (lower) activity, exemplified by dimethoxyphenyl analogue **2c**. Modelling suggested that the best exit vector to selectively interfere with the non-conserved residues at the entrance of the PI3K ATP binding site (selectivity pocket) would be from the meta-position of the newly introduced phenyl group. In particular, our intention was to form a salt bridge with the non-conserved D832 side chain of the PI3K δ isoform with a hydrogen bond donor (e.g. a protonated amine) on the ligand (see Supplementary Figure 3). We probed this concept with a small library and in that way identified piperazine amide

2d as a lead compound, demonstrating potency on PI3K δ and significant selectivity over all other Class I PI3K isoforms as well as mTOR. Based on these encouraging results, we began to optimize substituents of the quinazoline in positions 4 and 6 (for synthetic details, see supporting information).

Table 2 shows that the biochemical activity of piperazine amide **2d** translates well to Rat-1 cells that have been transfected with myristoylated, and therefore constitutively active, PI3K α , β and δ isoforms without significant activity drop. Isoform selectivity observed for biochemical assays is maintained in the cellular assays. The cellular activity on PI3K δ was also replicated in murine splenocytes (measured as inhibition of anti-IgM-induced expression of the costimulatory molecule CD86 on B cells), yet a ca. 5-fold activity drop was observed. Due to its moderate lipophilicity and positive charge, piperazine amide **2d** is very soluble at neutral pH. Areas identified for improvement were interference with the hERG channel as well as metabolic instability in rat liver microsomes.

We found that the activity on PI3K δ could be preserved to a large extent by replacing the position-6 quinoline motif of **2d** with less lipophilic monocyclic features. A selection of these analogues is shown in Table 2 (compounds **3d-6d**). Whereas compounds **3d**, **4d** and **6d** still displayed significant selectivity towards the other PI3K isoforms, introduction of a meta-CF₃ substituent (**5d**) led to a potency increase of PI3K α and β in addition to a substantial rise in log P. Further translation of the cellular response to the splenocyte assay was generally better for less lipophilic derivatives, perhaps due to less unspecific binding to plasma proteins. The combination of the basic N-methyl piperazine and aromatic rings led to an overlap with the well-known hERG pharmacophore and thus to a substantial inhibition in a dofetilide binding assay.²⁴ Decreasing the activity on the hERG channel was possible by lowering lipophilicity (e.g. compound **4d** and **6d**) assessed by a high-throughput (HT-) logP assay,²⁵ but a complete suppression, a clear project requirement, could not be achieved for these basic piperazine amides. Modulation of the microsomal turnover²⁶ for these derivatives also turned out to be possible to some degree, although overall clearance still remained high. In a rat PK experiment, compound **6d** showed substantial clearance (CL = 33 mL·min⁻¹·kg⁻¹, see Supplementary Table 1). Metabolite identification studies with **6d** suggested major metabolism around the piperazine moiety leading us to conclude that a major clearance reduction would not be possible without modifying this metabolic weak spot, ultimately leading to the introduction of a second amide functionality (Table 3). Pyridine **6e** and piperidine **6f** illustrate that the bridging phenyl ring can also be replaced by saturated or unsaturated heterocyclic rings, but as for all other analogues the impact on hERG and metabolism remained moderate.

We then discovered that the terminal piperazine N-methyl group could be substituted by short acyl groups. Table 3 outlines that N-acetyl piperazines **7**, **8**, **9** and **11** show an excellent potency profile on PI3K δ and selectivity profile over other PI3K isoforms. As for the N-methyl piperazine **5d**, addition of a meta-CF₃ group in the position-6 aromatic ring of the quinazoline was detrimental to isoform selectivity (compound **10**), presumably due to an H-bond between one of the fluorine atoms and the catalytic lysine. Due to the increased PSA of bis-amides compared to their mono-amide counterparts we noticed that PAMPA effective permeability (logP_e in 10⁻⁶ cm·sec⁻¹)²⁷ at neutral pH dropped, and that translation into cellular assays needed to be closely monitored. Compound **7** shows an >5-fold potency drop in the mouse splenocyte assay, a trend we noticed also for other compounds with HT-logP around 3 or above (data not shown), presumably due to an increased likelihood for unspecific binding. These observations led us to preferentially place compounds into the HT-logP window

between 2 and 3 to increase our chances for success. Bis-amides **7-11** are neutral and do not show any activity on the hERG channel up to 30 μ M. For many compounds, the piperazine acylation also led to significant metabolic stability increase in microsomal preparations.

As already mentioned, our initial design hypothesis to achieve isoform selectivity was based on forming a salt bridge between the ligand and D832. Neutral derivatives like acetylated piperazines **7-11** are not able to offer a hydrogen bond donor, and we were initially surprised by the observed selectivity. In order to elucidate the molecular reason, we co-crystallized compound **11** with PI3K α and PI3K δ , and these structures have been determined to 3 Å and 2.9 Å, respectively (see supporting information). In general, the structures reveal an overall fold similar to previous structures solved in complex with other inhibitors²⁸. The ligand is bound in the ATP site of the kinase domains, and forms an identical, direct hydrogen bond to V828 (δ) or V850 (α) in the hinge and with K779 (δ) or K802 (α) in the affinity-pocket of the active site (see Supplementary Figure 2). Water-mediated hydrogen bonds are formed with the side chain oxygens of D787 and Y813 in the affinity pocket and with the backbone carbonyl oxygen of S813 at the ATP binding site cleft, as observed in the slightly better resolved PI3K δ structure. The acetyl-piperazine group of the ligand stacks to W760 in the PI3K δ structure (Figure 1, right panel), which leads to strong attractive dispersion forces. In PI3K α , this interaction is not possible because R770 - in contrast to the smaller T750 in the δ isoform - blocks the access to the corresponding tryptophan W780 and the ligand protrudes from the ATP binding pocket in an extended conformation (Figure 1, left panel). The solvent-exposed, electrostatic interaction between R770 and compound **11** in PI3K α cannot compensate the van der Waals interactions between the acetyl-piperazine ring and the protein in the PI3K δ complex resulting in a preference of compound **11** for the PI3K δ isoform. Force field refinements of the original coordinates^{29,30} induced only minor local changes and provide further support for these observations. Binding free energies that were calculated by MM/GBSA computations on the energy-refined crystal structures of compound **11**, using the Amber Generalized-Born (GB) options igb = 2 or 5 confirm a preference of PI3K δ by 1.7 (igb=5) to 2.1 (igb=2) kcal/mol.³¹

Compound **11** showed selectivity against 3 lipid kinases, 40 protein kinases and 36 targets of an internal safety panel (full list, see Supporting Information). As it was the compound with the most promising overall in vitro profile, it was selected for further pharmacological characterization including its effects on isoform-dependent immune cell function. Since PI3K δ has been described as essential for B cell activation and function,^{14,32,33} we measured the effect of compound **11** on human and rodent B cell activation. Our data demonstrate a consistent and potent inhibition of PI3K δ -mediated B cell functions across different species (Table 4). Proximal readout parameters such as pAkt were equally well inhibited as further downstream events such as surface activation markers CD69 /CD86 or proliferation.

To assess whether compound **11** was suitable for in vivo studies, we tested its pharmacokinetic properties in rats and dogs (Table 5). At an oral dose of 3 mg/kg, compound **11** showed a moderate 22% oral bioavailability in rats. While a higher total exposure could be reached with increasing the dose to 30 mg/kg, this overall gain was not dose-linear, and bioavailability dropped to 10%, likely due to solubility limited absorption. In dogs, overall pharmacokinetic properties for compound **11** were similar (low clearance and low volume of distribution), with a somewhat better 42% oral bioavailability at 0.3 mg/kg. Overall, we concluded that compound **11** had adequate pharmacokinetic properties to assess the translation of inhibiting B cell activation in vitro to the in vivo situation. To this end, PK/PD studies were performed in rodents

following a single oral dose of compound **11** (30 mg/kg) in male Lewis rats. Blood was collected at various time points, and changes for two PD biomarker expression profiles as well as drug levels were determined (Figure 2). In agreement with the PK experiment in Sprague Dawley (SD) rats, compound concentration in Lewis rat blood reached a maximum after 2 hours with blood levels around 5 μ M. A clear relationship of drug exposure and inhibition of Akt phosphorylation and anti-IgM/rIL-4-induced CD86 expression was observed. Within the test samples, the highest pAkt inhibition (88%) was observed 6 hours after compound administration, whereas inhibition of CD86 expression was at its maximum of 71% already after 2 hours.

As a consequence of these encouraging results on the proximal PD markers, compound **11** was profiled in an ex vivo plaque forming cell (PFC) assay.³⁴ This mechanistic assay quantitatively determines the antibody-producing B cell response following immunization with sheep red blood cells (SRBC). After four days of compound treatment, rats were sacrificed and inhibition of plaques formed due to the SRBC specific B cell antibody response was assessed via the PFC assay (figure 3). At a dose of 10 mg/kg bid, plaque formation (vehicle mean $4.18 \cdot 10^5$ PFC/spleen) was inhibited by 79% (95% confidence interval [CI] = 56 to 92 percentage points, $p < 0.001$). At 30 mg/kg bid, an inhibition of 94% (95% CI = 89 to 97 percentage points, $p < 0.001$) was achieved comparable to the inhibition seen with the positive control CsA (Cyclosporin A, 95% CI = 84 to 98 percentage points, $p < 0.001$). Full statistics can be found in the supporting information.

In summary, we have identified novel quinazoline based PI3K δ selective inhibitors that we could optimize into cellularly potent derivatives. With compound **11** we profiled a candidate with good basic pharmacokinetic properties, however we observed an underproportional exposure increase at higher doses very likely caused by limited solubility. Compound **11** demonstrated that the PI3K δ -dependent inhibition of B cell activation observed in vitro and in rodent PK/PD studies translates into the full inhibition of B cell function, namely the T-dependent specific antibody response in vivo. These results confirmed our initial target hypothesis and encouraged us to continue our search for a suitable development candidate.

ASSOCIATED CONTENT

Supporting Information

Full descriptions of all biological assays and in vivo studies. Characterization of all compounds. Full experimental procedures for the sequence leading to compound **11**. Crystallographic data collection and refinement statistics for crystal structures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Accession Codes

PDB codes for X-ray crystal structures described in this study have been deposited in the Protein Data Bank under the following accession codes: 5IS5 (compound **11** in complex with PI3K δ) and 5ITD (compound **11** in complex with PI3K α).

AUTHOR INFORMATION

Corresponding Authors

*(K.H.) Tel: +41 79 6181814. E-mail: klemens.hoegenauer@novartis.com.

*(N.S.) Tel: +41 79 8451506. nicolas.soldermann@novartis.com.

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENTS

We thank I. Adam, J. Andre, I. Jeulin, D. Rageot, R. Strang, B. Thai and V. Tuccioni for their synthetic contributions, D. Fabbro, D. Haasen, A. Hinz, U. McKeever and P. Schmutz for their efforts towards developing and running biochemical and cellular assays, C. Beerli for pharmacokinetic assay work, B. Shrestha for protein expression, R. Elling for crystallography support as well as N. G. Cooke and G. Weckbecker for scientific guidance. We are grateful to the MX beamline team at the Swiss Light Source (PSI Villigen, Switzerland) for outstanding support at the beamline and Expose GmbH (Switzerland) for diffraction data collection.

ABBREVIATIONS

BAV, absolute oral bioavailability; hERG, human ether-à-go-related gene; MM/GBSA, molecular mechanics energies combined with the generalized Born and surface area continuum solvation method; mTOR, mechanistic target of rapamycin; PFC, plaque forming cell(s); PI3K, Phosphoinositide-3-kinase; SD rats, Sprague Dawley rats; SRBC, sheep red blood cell(s).

REFERENCES

- (1) Cantley, L. C. The Phosphoinositide 3-Kinase Pathway. *Science* **2002**, *296* (5573), 1655–1657.
- (2) Hawkins, P. T.; Stephens, L. R. PI3K Signalling in Inflammation. *Biochim. Biophys. Acta BBA - Mol. Cell Biol. Lipids* **2015**, *1851* (6), 882–897.
- (3) Geering, B.; Cutillas, P. R.; Nock, G.; Gharbi, S. I.; Vanhaesebroeck, B. Class IA Phosphoinositide 3-Kinases Are Obligate p85-p110 Heterodimers. *Proc. Natl. Acad. Sci.* **2007**, *104* (19), 7809–7814.
- (4) Marone, R.; Cmiljanovic, V.; Giese, B.; Wymann, M. P. Targeting Phosphoinositide 3-kinase—Moving towards Therapy. *Biochim. Biophys. Acta BBA - Proteins Proteomics* **2008**, *1784* (1), 159–185.
- (5) Maira, S.-M.; Voliva, C.; Garcia-Echeverria, C. Class IA Phosphatidylinositol 3-Kinase: From Their Biologic Implication in Human Cancers to Drug Discovery. *Expert Opin. Ther. Targets* **2008**, *12* (2), 223–238.
- (6) Foster, J. G.; Blunt, M. D.; Carter, E.; Ward, S. G. Inhibition of PI3K Signaling Spurs New Therapeutic Opportunities in Inflammation/Autoimmune Diseases and Hematological Malignancies. *Pharmacol. Rev.* **2012**, *64* (4), 1027–1054.
- (7) Rommel, C.; Camps, M.; Ji, H. PI3K δ and PI3K γ : Partners in Crime in Inflammation in Rheumatoid Arthritis and Beyond? *Nat Rev Immunol* **2007**, *7* (3), 191–201.
- (8) Stark, A.-K.; Sriskantharajah, S.; Hessel, E. M.; Okkenhaug, K. PI3K Inhibitors in Inflammation, Autoimmunity and Cancer. *Curr. Opin. Pharmacol.* **2015**, *23*, 82–91.
- (9) Hirsch, E.; Katanaev, V. L.; Garlanda, C.; Azzolino, O.; Pirola, L.; Silengo, L.; Sozzani, S.; Mantovani, A.; Altruda, F.; Wymann, M. P. Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation. *Science* **2000**, *287* (5455), 1049–1053.
- (10) Li, Z.; Jiang, H.; Xie, W.; Zhang, Z.; Smrcka, A. V.; Wu, D. Roles of PLC- β 2 and - β 3 and PI3K γ in Chemoattractant-Mediated Signal Transduction. *Science* **2000**, *287* (5455), 1046–1049.
- (11) Patrucco, E.; Notte, A.; Barberis, L.; Selvetella, G.; Maffei, A.; Brancaccio, M.; Marengo, S.; Russo, G.; Azzolino, O.; Rybalkin, S. D.; Silengo, L.; Altruda, F.; Wetzker, R.; Wymann, M. P.; Lembo, G.; Hirsch, E. PI3K γ Modulates the Cardiac Response to Chronic Pressure Overload

by Distinct Kinase-Dependent and -Independent Effects. *Cell* **2004**, *118* (3), 375–387.

(12) Clayton, E.; Bardi, G.; Bell, S. E.; Chantry, D.; Downes, C. P.; Gray, A.; Humphries, L. A.; Rawlings, D.; Reynolds, H.; Vigorito, E.; Turner, M. A Crucial Role for the PI3K δ Subunit of Phosphatidylinositol 3-Kinase in B Cell Development and Activation. *J. Exp. Med.* **2002**, *196* (6), 753–763.

(13) Jou, S.-T.; Carpino, N.; Takahashi, Y.; Piekorz, R.; Chao, J.-R.; Carpino, N.; Wang, D.; Ihle, J. N. Essential, Nonredundant Role for the Phosphoinositide 3-Kinase p110 δ in Signaling by the B-Cell Receptor Complex. *Mol. Cell. Biol.* **2002**, *22* (24), 8580–8591.

(14) Okkenhaug, K.; Bilancio, A.; Farjot, G.; Priddle, H.; Sancho, S.; Peskett, E.; Pearce, W.; Meek, S. E.; Salpekar, A.; Waterfield, M. D.; Smith, A. J. H.; Vanhaesebroeck, B. Impaired B and T Cell Antigen Receptor Signaling in p110 δ PI 3-Kinase Mutant Mice. *Science* **2002**, *297* (5583), 1031–1034.

(15) Sadhu, C.; Masinovsky, B.; Dick, K.; Sowell, C. G.; Staunton, D. E. Essential Role of Phosphoinositide 3-Kinase δ in Neutrophil Directional Movement. *J. Immunol.* **2003**, *170* (5), 2647–2654.

(16) Park, S. J.; Lee, K. S.; Kim, S. R.; Min, K. H.; Moon, H.; Lee, M. H.; Chung, C. R.; Han, H. S.; Puri, K. D.; Lee, Y. C. Phosphoinositide 3-Kinase δ Inhibitor Suppresses Interleukin-17 Expression in a Murine Asthma Model. *Eur. Respir. J.* **2010**, *36* (6), 1448–1459.

(17) Durand, C. A.; Richer, M. J.; Brenker, K.; Graves, M.; Shaniya, I.; Choi, K.; Horwitz, M. S.; Puri, K. D.; Gold, M. R. Selective Pharmacological Inhibition of Phosphoinositide 3-Kinase p110 δ Opposes the Progression of Autoimmune Diabetes in Non-Obese Diabetic (NOD) Mice. *Autoimmunity* **2013**, *46* (1), 62–73.

(18) Norman, P. Selective PI3K δ Inhibitors, a Review of the Patent Literature. *Expert Opin. Ther. Pat.* **2011**, *21* (11), 1773–1790.

(19) Bui, M.; Hao, X.; Shin, Y.; Cardozo, M.; He, X.; Henne, K.; Suchomel, J.; McCarter, J.; McGee, L. R.; San Miguel, T.; Medina, J. C.; Mohn, D.; Tran, T.; Wannberg, S.; Wong, J.; Wong, S.; Zalameda, L.; Metz, D.; Cushing, T. D. Synthesis and SAR Study of Potent and Selective PI3K δ Inhibitors. *Bioorg. Med. Chem. Lett.* **2015**, *25* (5), 1104–1109.

(20) Cushing, T. D.; Hao, X.; Shin, Y.; Andrews, K.; Brown, M.; Cardozo, M.; Chen, Y.; Duquette, J.; Fisher, B.; Gonzalez-Lopez de Turiso, F.; He, X.; Henne, K. R.; Hu, Y.-L.; Hungate, R.; Johnson, M. G.; Kelly, R. C.; Lucas, B.; McCarter, J. D.; McGee, L. R.; Medina, J. C.; San Miguel, T.; Mohn, D.; Pattaropong, V.; Pettus, L. H.; Reichelt, A.; Rza, R. M.; Segansh, J.; Tasker, A. S.; Wahl, R. C.; Wannberg, S.; Whittington, D. A.; Whoriskey, J.; Yu, G.; Zalameda, L.; Zhang, D.; Metz, D. P. Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-Yl)quinolin-3-Yl)ethyl)-9H-Purin-6-Amine (AMG319) and Related PI3K δ Inhibitors for Inflammation and Autoimmune Disease. *J. Med. Chem.* **2015**, *58* (1), 480–511.

(21) Shin, Y.; Suchomel, J.; Cardozo, M.; Duquette, J.; He, X.; Henne, K.; Hu, Y.-L.; Kelly, R. C.; McCarter, J.; McGee, L. R.; Medina, J. C.; Metz, D.; San Miguel, T.; Mohn, D.; Tran, T.; Vissinga, C.; Wong, S.; Wannberg, S.; Whittington, D. A.; Whoriskey, J.; Yu, G.; Zalameda, L.; Zhang, X.; Cushing, T. D. Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3K δ Inhibitors. *J. Med. Chem.* **2016**, *59* (1), 431–447.

(22) Maira, S.-M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chène, P.; Pover, A. D.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and Characterization of NVP-BEZ235, a New Orally Available Dual Phosphatidylinositol 3-Kinase/mammalian Target of Rapamycin Inhibitor with Potent in Vivo Antitumor Activity. *Mol. Cancer Ther.* **2008**, *7* (7), 1851–1863.

(23) Camps, M.; Ruckle, T.; Ji, H.; Ardisson, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Francon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P.-A.; Hirsch, E.; Wymann, M. P.; Cirillo, R.; Schwarz, M. K.; Rommel, C. Blockade of PI3K γ Suppresses Joint Inflammation and Damage in Mouse Models of Rheumatoid Arthritis. *Nat Med* **2005**, *11* (9), 936–943.

(24) Finlayson, K.; Turnbull, L.; January, C. T.; Sharkey, J.; Kelly, J. S. [3H]Dofetilide Binding to HERG Transfected Membranes: A Potential High Throughput Preclinical Screen. *Eur. J. Pharmacol.* **2001**, *430* (1), 147–148.

(25) Faller, B.; Grimm, H. P.; Loeuillet-Ritzler, F.; Arnold, S.; Briand, X. High-Throughput Lipophilicity Measurement with Immobilized Artificial Membranes. *J. Med. Chem.* **2005**, *48* (7), 2571–2576.

(26) Trunzer, M.; Faller, B.; Zimmerlin, A. Metabolic Soft Spot Identification and Compound Optimization in Early Discovery Phases

Using MetaSite and LC-MS/MS Validation. *J. Med. Chem.* **2009**, *52* (2), 329–335.

(27) Faller, B. Artificial Membrane Assays to Assess Permeability. *Curr. Drug Metab.* **2008**, *9* (9), 886–892.

(28) Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W.-C.; Liu, Y.; Rommel, C.; Gaillard, P.; Ruckle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p110 δ Crystal Structure Uncovers Mechanisms for Selectivity and Potency of Novel PI3K Inhibitors. *Nat. Chem. Biol.* **2010**, *6* (2), 117–124.

(29) Maier, J. A.; Martinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K. E.; Simmerling, C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. *J. Chem. Theory Comput.* **2015**, *11* (8), 3696–3713.

(30) Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and Testing of a General Amber Force Field. *J. Comput. Chem.* **2004**, *25* (9), 1157–1174.

(31) Case, D. A.; Berryman, J. T.; Betz, R. M.; Cerutti, D. S.; Cheatham, III, T. E.; Darden, T. A.; Duke, R. E.; Giese, T. J.; Gohlke, H.; Goetz, A. W.; Homeyer, N.; Izadi, S.; Janowski, P.; Kaus, J.; Kovalenko, A.; Lee, T. S.; LeGrand, S.; Li, P.; Luchko, T.; Luo, R.; Madej, B.; Merz, K. M.; Monard, G.; Needham, P.; Nguyen, H.; Nguyen, H. T.; Omelyan, I.; Onufriev, A.; Roe, D. R.; Roitberg, A.; Salomon-Ferrer, R.; Simmerling, C. L.; Smith, W.; Swails, J.; Walker, R. C.; Wang, J.; Wolf, R. M.; Wu, X.; York, D. M.; Kollman, P. A. *AMBER 2015*; University of California, San Francisco, 2015.

(32) Pinho, V.; Russo, R. de C.; Amaral, F. A.; Sousa, L. P. de; Barsante, M. M.; Souza, D. G. de; Alves-Filho, J. C.; Cara, D. C.; Hayflick, J. S.; Rommel, C.; Ruckle, T.; Rossi, A. G.; Teixeira, M. M. Tissue- and Stimulus-Dependent Role of Phosphatidylinositol 3-Kinase Isoforms for Neutrophil Recruitment Induced by Chemoattractants In Vivo. *J. Immunol.* **2007**, *179* (11), 7891–7898.

(33) Soond, D. R.; Björge, E.; Moltu, K.; Dale, V. Q.; Patton, D. T.; Torgersen, K. M.; Galleway, F.; Twomey, B.; Clark, J.; Gaston, J. S. H.; Taskén, K.; Bunyard, P.; Okkenhaug, K. PI3K p110 δ Regulates T-Cell Cytokine Production during Primary and Secondary Immune Responses in Mice and Humans. *Blood* **2010**, *115* (11), 2203–2213.

(34) Jerne, N. K.; Nordin, A. A. Plaque Formation in Agar by Single Antibody-Producing Cells. *Science* **1963**, *140* (3565), 405–405.




Figure 1. Co-crystal structures of PI3K α (left panel) and PI3K δ (right panel) in complex with compound **11**. The protein is shown as grey surface and the inhibitor is represented as green sticks. Whereas compound **11** stacks onto W760 in PI3K δ , R770 in PI3K α forces the inhibitor to adopt an extended conformation. Key amino acid residues are highlighted in color.




Figure 2. Rat PK/PD for compound **11** at 30 mg/kg p.o. single dose: inhibition of ex vivo induced B cell activation in 50% whole blood; PK legend at the left, PD legend at the right; error bars indicate standard deviation.





Figure 3. Dose-dependent inhibition of SRBC-specific IgM response by compound **11**; error bars indicate standard deviation; ***: $p < 0.001$ compared to vehicle (student's t-test, two-tailed distribution).

Table 1. Influence of position-4 substituents of the quinazoline on overall potency, PI3K isoform selectivity and selectivity towards mTOR



	biochemical IC ₅₀ [μM] ^a				
	PI3Kα ^b	PI3Kβ ^b	PI3Kγ ^c	PI3Kδ ^c	mTOR ^d
1	0.017	0.192	0.313	0.025	0.006
2a	0.650	>10	>10	8.1	>10
2b	0.090	3.2	5.6	0.320	0.66
2c	0.095	1.9	2.6	0.061	1.8
2d	0.633	>10	>10	0.049	5.3

^aMean of a minimum of two independent experiments; standard deviation for pIC₅₀ values <0.3; ^bKGlo format; ^cADAPTA format (values comparable to KGlo); ^dradiometric protein kinase assay.

Table 4. Cellular inhibition of PI3Kδ-dependent B cell activation in different species by compound **11**.

biochemical IC ₅₀ [μM] ^a						
human ^b		rat ^c		mouse ^d		
pAkt	CD86	CD69	pAkt	CD86	Prolif.	CD86
0.029	0.107	0.125	0.089	0.044	0.011	0.070

^aMean of a minimum of two independent experiments; standard deviation for pIC₅₀ values <0.3; ^bmeasured in 90% whole blood; ^cmeasured in 50% whole blood; ^dmeasured in splenocytes

Table 5. PK parameters^a for compound **11**.

Species	Rat ^b	Rat ^b	Rat ^b	Dog ^c	Dog ^c
Dose [mg·kg ⁻¹]	1 (iv)	3 (po)	30 (po)	0.1 (iv)	0.3 (po)
CL [mL·min ⁻¹ ·kg ⁻¹]	15 (3)		13 (3)		
V _{SS} [L·kg ⁻¹]	2.0 (0.3)		1.0 (0.2)		
t _{1/2} term. [h]	2.0 (0.5)		0.9 (0.1)		
AUC d.n. ^d [nM·h]	2315 (537)	500 (168)	237 (24)	2798 (715)	1188 (251)
BAV [%]	22 (7)		10 (1)	42 (9)	
C _{max} d.n. ^d [nM]	48 (14)		20 (4)	440 (112)	
T _{max} [h]	3.5 (3.1)	5.3 (2.2)	0.8 (0.3)		

^amean values (rat: n = 4, dog: n = 3) with standard deviation in brackets, ^bfemale, ^cmale, ^dd.n. = dose normalized to 1 mg·kg⁻¹

TOC graphic






Table 2. Influence of position-4 and -6 substituents of the quinazoline on biochemical/cellular potency, PI3K isoform selectivity, hERG inhibition and in vitro ADME parameters


R	biochemical IC ₅₀ [μM] ^a				cellular IC ₅₀ [μM] ^{a, d}			mCD86 IC ₅₀ [μM] ^{a, e}	PAMPA logP _e ^f	hERG IC ₅₀ [μM] ^g	HT-logP ^h	RLM CL _{int} ^j	HT-sol ^k
	PI3Kα ^b	PI3Kβ ^b	PI3Kγ ^c	PI3Kδ ^c	PI3Kα	PI3Kβ	PI3Kδ						
2d	0.633	>10	>10	0.049	1.14	>12.5	0.038	0.190	-3.9	2.6	3.1	>700	>1.0
3d	0.410	2.57	0.740	0.014	1.09	4.89	0.018	0.026	-4.1	1.9	2.8	357	0.85
4d	0.283	2.63	9.2	0.027	1.56	1.91	0.037	0.087	-4.2	11	1.9	231	0.42
5d	0.079	0.392	9.3	0.009	0.40	0.38	0.010	0.074	-3.6	1.6	3.9	213	0.85
6d	0.259	4.15	7.9	0.020	1.56	1.91	0.037	0.087	-3.7	12	2.2	605	>1.0
6e	0.462	6.18	>10	0.100 ^m	2.49	7.54	0.036	0.112	-4.4	26	1.9	201	>1.0
6f	0.399	2.04	4.5	0.064 ^m	1.82	4.62	0.070	0.086	-3.8	1.5	nd ⁿ	130	>1.0

^aMean of a minimum of two independent experiments; standard deviation for pIC₅₀ values <0.3; ^bKGlo format; ^cADAPTA format (values comparable to KGlo); ^dinhibition of pAkt formation in Rat-1 cells; ^einhibition of anti-IgM induced mCD86 expression on mouse splenocytes; ^feffective permeability [10⁻⁶ cm·sec⁻¹] (pH = 6.8), n=1; ^ginhibition of [3H]dofetilide binding to hERG transfected membranes, n=1; ^hHigh-throughput logP measurement with immobilized artificial membranes, n=1; ⁱintrinsic clearance in incubations of rat liver microsomes [μL·min⁻¹·mg⁻¹ protein], n=1; ^jHigh-throughput equilibrium solubility determination [mM] (pH = 6.8); ^mlow Hill coefficient; ⁿnd = not determined

Table 3. Influence of position-6 substituents of the quinazoline on biochemical/cellular potency, PI3K isoform selectivity, hERG inhibition and in vitro ADME parameters


R	biochemical IC ₅₀ [μM] ^a				cellular IC ₅₀ [μM] ^{a, d}			mCD86 IC ₅₀ [μM] ^{a, e}	PAMPA logP _e ^f	hERG IC ₅₀ [μM] ^g	HT-logP ^h	RLM CL _{int} ^j	HT-sol ^k
	PI3Kα ^b	PI3Kβ ^b	PI3Kγ ^c	PI3Kδ ^c	PI3Kα	PI3Kβ	PI3Kδ						
7	0.829	4.27	5.6	0.003	2.10	4.65	0.062	0.393	-5.3	>30	2.8	525	0.61
8	0.127	1.94	0.220	0.014	1.32	3.38	0.039	0.034	-5.1	>30	1.9	68	0.80
9	0.418	4.84	2.7	0.029	2.12	3.57	0.028	0.070	-4.9	>30	2.7	115	>1.0
10	0.084	0.536	1.4	0.005	0.690	2.07	0.014	0.093	-4.1	>30	3.1	83	0.38
11	0.262	1.65	4.63	0.009	3.44	6.53	0.049	0.074	-5.5	>30	2.8	63	0.21

^aMean of a minimum of two independent experiments; standard deviation for pIC₅₀ values <0.3; ^bKGlo format; ^cADAPTA format (values comparable to KGlo); ^dinhibition of pAkt formation in Rat-1 cells; ^einhibition of anti-IgM induced mCD86 expression on mouse splenocytes; ^feffective permeability [10⁻⁶ cm·sec⁻¹] (pH = 6.8), n=1; ^ginhibition of [3H]dofetilide binding to hERG transfected membranes, n=1; ^hHigh-throughput logP measurement with immobilized artificial membranes, n=1; ⁱintrinsic clearance in incubations of rat liver microsomes [μL·min⁻¹·mg⁻¹ protein], n=1; ^jHigh-throughput equilibrium solubility determination [mM] (pH = 6.8); ⁿnd = not determined